For Pharma, Biotech, CDMOs

Catch the CAPA patterns FDA cites in 30 seconds.

Taktly grades your CAPA, deviation investigation, A3, charter, root cause, and full DMAIC work against the exact patterns FDA writes into Warning Letters. The audit is free, your data stays in your tenant, and you walk away with a rewritten document — in practitioner voice — that an MBB would actually approve.

21 CFR 21121 CFR 820ICH Q9 (Risk)ICH Q10 (PQS)ICH Q7 (API)EU GMP Annex 1Sterile fill-finishBiologicsVaccinesCell & gene therapyAPI / fine chemicalsGenericsPlasma & bloodCDMOs
or paste

Free · No signup · 30 seconds · Your data stays in your tenant

Free · No signup · 30 seconds · Your data stays in your tenant

FDA Warning Letter patterns

The exact patterns auditors cite — and Taktly flags before they ship.

Each card is a paraphrased pattern from a real public FDA action. Taktly's engine carries this corpus and runs your document against it on every audit. Hover a card to see the real citation.

Operator-error attributed as terminal root cause

483 likely

FDA consistently cites firms that stop the investigation at 'operator error' without identifying the system condition that allowed the error. This pattern reliably draws a 483 for inadequate root cause investigation.

Aspen Pharmacare (paraphrased) · FY2023

FDA Warning Letter to Aspen Notre Dame de Bondeville (FY2023) — case reference on file

FDA noted the firm's investigation concluded with operator error as the cause without addressing why the procedural design, training adequacy, or shift staffing allowed the error to occur unchecked. The agency required a CAPA addressing systemic factors, not just retraining of the named operator.

Training-only CAPA in regulated environment

483 likely

ICH Q9 and FDA expect CAPAs to address the hierarchy of controls. Training is the weakest control. FDA routinely cites firms that respond to a deviation with retraining as the sole or primary CAPA when engineering or procedural controls were available.

Lupin Limited (paraphrased) · FY2023

FDA Warning Letter to Lupin Pithampur (FY2023) — case reference on file

FDA found CAPAs that relied solely on retraining without addressing the absence of automated checks at the deviation point. The agency cited inadequate hierarchy of controls and required systemic CAPAs in addition to any training response.

'Continue to monitor' as effectiveness check

483 likely

An effectiveness check that says 'monitor going forward' or 'track for recurrence' contains no closure criterion, no threshold, and no sample-size commitment. FDA cites this routinely in CAPA-inadequacy findings.

Cipla USA (paraphrased) · FY2023

FDA Warning Letter to Cipla Goa (FY2023) — case reference on file

FDA found that effectiveness checks for multiple CAPAs lacked predefined acceptance criteria, sample sizes, or closure thresholds. The agency noted that 'continue to monitor' is not a check and required revised CAPAs with measurable closure criteria.

Undefined success / target language

WL cited

An improvement project or CAPA without a measurable, time-bound target cannot be closed or validated. FDA flags vague 'industry standard' or 'acceptable' targets in CAPA effectiveness reviews.

Macleods Pharmaceuticals (paraphrased) · FY2023

FDA Warning Letter to Macleods Sikkim (FY2023) — case reference on file

FDA noted that CAPA targets were stated as 'acceptable levels' without specific numeric thresholds. The agency required quantified targets with documented justification for each metric.

No documented prior-occurrence search

WL cited

Tier 3+ events require a documented prior-occurrence search to establish whether the event is isolated or recurring. Without it, the systemic dimension is undocumented and the CAPA cannot defend its scope.

Sun Pharmaceutical (paraphrased) · FY2022

FDA Warning Letter to Sun Halol (FY2022) — case reference on file

FDA found that investigations did not include searches of prior similar events. The agency cited inadequate scope of investigation and required CAPAs to consider trend data and recurrence history.

No MSA on subjective visual inspection

WL cited

Visual inspection is a subjective measurement system. Without an MSA, observed reject rate may reflect inspector variation rather than process variation, undermining any subsequent root cause work.

Hospira (paraphrased) · FY2022

FDA Warning Letter — Hospira fill-finish facility

FDA found that visual inspection rejection rates were tracked without any documented attribute-agreement study on the inspectors. The agency required an MSA before using inspection data as a process performance metric.

“If your CAPA's effectiveness check says 'continue to monitor,' your investigation ends with 'operator error,' or your target is 'industry standard,' you're already on the audit risk register. Taktly catches all three before the document leaves your inbox.”

Pharma & Biotech · Before / After

Same project. Before Taktly, and after.

Three examples tuned to pharma & biotechwork. The left column is what teams actually write. The right column is what Taktly rewrites it to — using your project's real context, in practitioner voice.

Operator-error root cause on a sterility positive

Before

Root cause: Operator failed to follow the CIP cleaning SOP at the changeover, leading to contamination of Lot R-2401.

After Taktly

The CIP cycle-time deviation that produced contamination of Lot R-2401 was undetectable in real-time: the recipe permitted manual override of minimum cycle time with no alarm, no QA notification, and no automated batch-record flag. The deviation propagated to fill because the next inspection point was post-aseptic, after contamination would already be present.

Why the reviewer would push back: FDA does not accept human-error as a root cause. There is no system change in this statement — the same operator on the same SOP will produce the same result next changeover.

Training-only CAPA on a deviation

Before

Corrective action: Retrain all line operators on the updated work instruction. Effectiveness: confirm all operators have signed off on the training matrix.

After Taktly

Containment: Hold all in-process units pending re-inspection (owner: QA Mgr, due Day 3). Corrective: Replace the visual-inspection step with the new alarm-on-fail pressure check at station 4 (owner: Eng Mgr, due Day 30). Preventive: Hard-code the pressure spec in the line PLC so override requires QA sign-off; add a daily torque-check log entry (owner: Eng Mgr, due Day 60). Training is paired with the system change, not substituted for it. Effectiveness: ≥ 60-batch post-implementation window with pressure-fail rate < 0.5% sustained, Cpk ≥ 1.33; closure decision at the 90-day QA review.

Why the reviewer would push back: Training without a system-level change does not prevent recurrence in regulated environments. A training-only CAPA is reviewer-flagged as inadequate root cause investigation under 21 CFR 211 / 21 CFR 820.

Vague effectiveness check on a Class III deviation

Before

Effectiveness will be monitored over the next 6 months. Trend data will be reviewed by QA.

After Taktly

Effectiveness check: Re-measure visual-inspection reject rate on Line 2 over 30 consecutive batches (~n=8,000 vials) starting 30 days post-implementation. Success: reject rate < 2.0% sustained over the window, with B-shift in-window reject rate below 3.0%. Cpk for the B-shift sub-window ≥ 1.0. Re-measurement methodology must match the baseline methodology (visual inspection per SOP QC-VI-014). QA closure decision at the 90-day review; auto-reopen if the 30-day or 60-day checkpoint shows a regression of > 1 pp.

Why the reviewer would push back: FDA explicitly cites 'continue to monitor' language in CAPA-inadequacy 483s. There is no threshold, no sample size, and no closure criterion.

Pharma & Biotech

Drop your project. Get a senior review in 30 seconds.

Free. No signup. Your data stays in your tenant. Taktly scores your document against the 21 CFR 211 patterns above and hands you back a rewritten version you can keep working in.

Start the senior reviewStart a free project

Taktly for other industries

Medical DeviceFood Manufacturing